Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two components: - **Placebo** is an inactive substance or treatment designed to have no therapeutic effect, often used as a control in clinical trials. - **Midazolam** is a short-acting benzodiazepine with rapid onset, used primarily for its sedative, anxiolytic, muscle relaxant, anticonvulsant, and amnesic properties. It acts by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor in the central nervous system. Midazolam is commonly administered before medical procedures or anesthesia to induce sedation and reduce anxiety and memory of events. It can also be used for acute seizure management and as part of anesthesia induction[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placebo + midazolam.